This content is password protected. To view it please enter your password below: Password: The post Protected: Announcing a $1.5M international partnership with LifeArc to co-fund high-grade glioma research  appeared first on CureSearch for Children's Cancer ..read more

The prognosis for metastatic Ewing sarcoma can be devastating. Dr. Lee’s research may change that. Ewing sarcoma (ES) is a bone cancer that can be difficult to treat once it has spread. The 5-year survival rate for children with the advanced disease remains alarmingly poor, as low as 15%. Children with ES need new treatment options now. In a groundbreaking development for pediatric ES research, we’re excited to share news of our latest funded research project led by Dr. John Lee of the David Geffen School of Medicine at UCLA. Dr. Lee is the latest recipient of our Acceleration Initiative Award ..read more

Dr. Joshua Breunig, PhD, of Cedars-Sinai, is a 2024 CureSearch Acceleration Initiative AwardeeThe urgent need for advanced childhood brain cancer research G34R-mutant pediatric diffuse glioma, a devastating brain cancer affecting children and young adults, poses significant challenges in treatment due to its aggressive nature, limited therapeutic options, and the long-term side effects. The urgent need for more effective treatment options drives researchers, like Dr. Joshua Breunig, to innovate. One major obstacle in developing these treatments has been the absence of accurate preclinical mode ..read more

Dr. Joshua Breunig Pediatric glioma, a devastating brain cancer affecting children and young adults, poses significant challenges in treatment due to its aggressive nature, limited therapeutic options, and the long-term side effects. The urgent need for more effective treatment options drives researchers like Dr. Breunig to innovate. One major obstacle in developing these treatments has been the absence of accurate preclinical models for testing potential therapies. Dr. Breunig’s groundbreaking approach, utilizing MADR (Mosaic Analysis with Dual Recombinases), enables the creation of personali ..read more

Dr. Hunter Jonus Neuroblastoma is the most common extracranial solid tumor of childhood arising within the developing nervous system. Approximately half of neuroblastoma patients are diagnosed with high-risk disease, which is especially aggressive with a 50% survival rate. If a child’s high-risk neuroblastoma relapses after receiving chemotherapy, overall survival plummets below 20%. The few children that do survive often suffer significant long-term treatment related toxicities and are at a higher risk for secondary malignancies.  Dr. Hunter Jonus, PhD, a CureSearch Young Investigator at ..read more

Dr. Babak Moghimi Acute Myeloid leukemia (AML) is the second most common leukemia in children, and the prognosis after relapse is poor. Unlike current CAR T treatment for the most common childhood leukemia, acute lymphoblastic leukemia (ALL), patients with AML experience significant toxicity with CAR T therapy. This is due, in part, to the CAR T’s target appearing on healthy cells and tumor cells, driving the therapy to attack both. Novel treatment approaches are in dire need as current AML CAR T-cells have failed to prolong survival for these very high-risk patients.   Dr. Moghimi a ..read more

Brave Barbie doll provides a friend through treatment for kids with cancer  Bethesda, Md. – October 23, 2023 – CureSearch for Children’s Cancer and Mattel are celebrating 10 years of Brave Barbie – a special Barbie created to bring hope and comfort to courageous young patients battling illness or receiving treatments that cause hair loss.  To help kids better understand and cope with hair loss, CureSearch and Mattel partnered to develop and distribute a Barbie that represents the young fighters undergoing cancer treatment.   “Brave Barbie is given to children that are goin ..read more

Monthly Supper Club supports CureSearch for Children’s Cancer  Holly Springs, N.C. – September 28, 2023 – Pimiento Tea Room, a unique tea house and restaurant in downtown Holly Springs, has raised more than $37,000 this year for CureSearch for Children’s Cancer, supporting pediatric cancer research.   In 2020, Matt and Christy Griffith transformed a historic 180-year-old farmhouse into the Holly Springs’ award-winning Pimiento Tea Room. Shortly after opening, the couple launched the monthly Supper Club, a seven-course event that features adventurous cuisine with a Southern ..read more

By Holly R. Zink, MSA, ACRP  Cancer in children differs from cancer in adults, from DNA alterations to tumor origin. More than 15,000 children are diagnosed with cancer each year in the U.S., and while new treatments — most often designed originally for adults — have increased overall survival rates, children often face longer, more intense treatment schedules. The need for tailored treatments is crucial.   Clinical trials connect more patients to new therapies, saving more lives  Current standard therapies for many childhood cancers are over 30 years old and have lifelong ..read more

Share on social media  Our Childhood Cancer Awareness Month (CCAM) Partner Toolkit contains social media posts and graphics, including a CCAM cover photo for Facebook and LinkedIn. Adding this cover photo to your page is a quick and easy way to show your support of CureSearch and children with cancer. Additionally, we encourage you to share content directly from the CureSearch social media channels. Hitting that share button on posts helps to build our page followers and boost our post visibility. Follow us on Facebook, Instagram, LinkedIn and ..read more